MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript Summary
MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript Summary
The company anticipates reaching adjusted EBITDA positivity in the first half of next year and has raised its full-year 2024 revenue guidance to $87 million to $89 million.The following is a summary of the MDxHealth SA (MDXH) Q3 2024 Earnings Call Transcript:
以下是MDxHealth SA (MDXH) 2024年第三季度業績會交易摘要:
Financial Performance:
財務表現:
MDxHealth reported a notable year-over-year revenue growth of 21% in Q3 2024, reaching $23.3 million.
Gross profit for Q3 2024 was $14.3 million, marking a 14% increase year-over-year.
The company anticipates reaching adjusted EBITDA positivity in the first half of next year and has raised its full-year 2024 revenue guidance to $87 million to $89 million.
Expectations include a consistent commercial execution and operating discipline aiming for sustainable growth.
MDxHealth報告2024年第三季度營業收入同比增長21%，達到2330萬美元。
2024年第三季度毛利潤爲1430萬美元，同比增長14%。
公司預計在明年上半年達到調整後的EBITDA盈利，並將2024年全年營業收入指導提高至8700萬至8900萬美元。
期望包括持續的商業執行和運營紀律，旨在實現可持續增長。
Business Progress:
業務進展:
MDxHealth continues to experience growth in its urology precision diagnostics, driven by an effective sales and market access team.
The company successfully raised $40 million in gross proceeds during Q3 to strengthen its financial position.
Expansion of the test menu in urology diagnostics includes the introduction of new tests like Germline, alongside the existing tests such as Confirm mdx, GPS, Select mdx, and Resolve mdx.
MDxHealth在泌尿科精準診斷領域持續增長，得益於高效的銷售和市場準入團隊。
公司在第三季度成功籌集了4000萬美元的毛利潤，以加強其財務狀況。
泌尿學診斷測試菜單的擴展包括引入新的檢測項目，如生殖細胞系，以及現有的檢測項目，如Confirm mdx，GPS，Select mdx和Resolve mdx。
Opportunities:
機會：
The growing leadership in urology precision diagnostics positions MDxHealth to capitalize on sustained and strong revenue growth.
The successful capital raise provides financial flexibility, supporting ongoing execution and future growth initiatives.
泌尿學精準診斷領域不斷增強的領導地位使MDxHealth能夠利用持續和強勁的營業收入增長。
成功的資本籌集提供了財務靈活性，支持持續的執行和未來的增長計劃。
Risks:
風險：
Operating loss for Q3 2024 widened to $6.1 million from $4.6 million year-over-year, reflecting increased expenses from clinical study and sales incentives despite growth.
The Gross margin percentage for Q3 2024 decreased to 61.2% from 64.9% in Q3 2023 due to backlog recognition from the prior year.
2024年第三季度的營業虧損從去年的460萬美元擴大到610萬美元，反映出在臨床研究和銷售激勵方面的支出增加，儘管有增長。
由於來自前一年的滯銷認定，2024年第三季度的毛利率從2023年第三季度的64.9%下降到61.2%。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。